Alprolix
Payments companies reported to CMS as associated with Alprolix. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Alprolix, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Alprolix
These are the largest totals companies reported as associated with Alprolix. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Maissaa Janbain | New Orleans, LA | Hematology & Oncology | $25,191.65 |
| Guillermo Deangulo | Miami, FL | Pediatric Hematology-Oncology | $21,793.43 |
| Doris Quon | Los Angeles, CA | Hematology (Internal Medicine) | $19,956.24 |
| Guy Young | Bozeman, MT | Pediatric Hematology-Oncology | $12,117.45 |
| Lynn Malec | Milwaukee, WI | Pediatric Hematology-Oncology | $11,675.08 |
| Jonathan Roberts | Peoria, IL | Pediatrics | $9,886.00 |
| Shveta Gupta | Orlando, FL | Pediatric Hematology-Oncology | $9,049.01 |
| Robert Sidonio | Atlanta, GA | Pediatric Hematology-Oncology | $8,017.14 |
| Vivek Sharma | Louisville, KY | Hematology & Oncology | $4,581.43 |
| Mindy Simpson | Chicago, IL | Pediatrics | $4,557.38 |
Prescribed Alprolix?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.